Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Common Equity (2017 - 2025)

Historic Common Equity for Regenerative Medical Technology (RMTG) over the last 9 years, with Q3 2025 value amounting to -$30.1 million.

  • Regenerative Medical Technology's Common Equity fell 1248.56% to -$30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.1 million, marking a year-over-year decrease of 1248.56%. This contributed to the annual value of -$27.4 million for FY2024, which is 2551.52% down from last year.
  • As of Q3 2025, Regenerative Medical Technology's Common Equity stood at -$30.1 million, which was down 1248.56% from -$29.0 million recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Common Equity registered a high of $3.3 million during Q2 2021, and its lowest value of -$30.1 million during Q3 2025.
  • For the 5-year period, Regenerative Medical Technology's Common Equity averaged around -$16.8 million, with its median value being -$15.7 million (2023).
  • Its Common Equity has fluctuated over the past 5 years, first surged by 12858.67% in 2021, then crashed by 39256.22% in 2022.
  • Quarter analysis of 5 years shows Regenerative Medical Technology's Common Equity stood at -$6.8 million in 2021, then crashed by 77.33% to -$12.0 million in 2022, then tumbled by 81.9% to -$21.8 million in 2023, then fell by 25.52% to -$27.4 million in 2024, then decreased by 9.86% to -$30.1 million in 2025.
  • Its Common Equity was -$30.1 million in Q3 2025, compared to -$29.0 million in Q2 2025 and -$28.1 million in Q1 2025.